Last reviewed · How we verify
Biological
At a glance
| Generic name | Biological |
|---|---|
| Also known as | Collagenase, Convalescent plasma, Dysbiosis |
| Sponsor | GAIA BioMedicine Inc. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (PHASE1)
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine (PHASE1)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |